• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

CORRECTING and REPLACING DOR BioPharma to Host Conference Call on Thursday, January 25 to Discuss Recently Published orBec(R) Phase 3 Clinical Results

Posted on: Wednesday, 24 January 2007, 18:01 CST

In the first sentence of the second graph, the U.S. dial-in number was incorrect. That number should read: 888-300-4091.

The corrected release reads:

DOR BIOPHARMA TO HOST CONFERENCE CALL ON THURSDAY, JANUARY 25 TO DISCUSS RECENTLY PUBLISHED ORBEC® PHASE 3 CLINICAL RESULTS

DOR BioPharma, Inc. (OTCBB:DORB) (DOR or the Company) announced today that it will host a conference call on Thursday, January 25, 2007 beginning at 11 a.m. Eastern time. Christopher J. Schaber Ph.D., President and Chief Executive Officer and author(s) of the Blood paper will discuss the publication as well as the long-term mortality data. The discussion will include detail on DOR's 129-patient pivotal Phase 3, randomized, double-blinded, placebo-controlled multi-center clinical trial of orBec® conducted at 16 leading bone marrow/stem cell transplant centers in the U.S. and France; and long-term survival data from its 60-patient Phase 2, randomized, double-blinded, placebo-controlled clinical trial conducted at the Fred Hutchinson Cancer Research Center.

To participate in the conference call please dial 888-300-4091 from the U.S. or 706-902-0808 from outside the U.S. Listeners also can join the webcast by logging into the Company's website at www.dorbiopharma.com approximately 10 minutes prior to the start of the call.

A replay of the call will be available beginning from 2:00 p.m. ET on January 25, 2007 by dialing 800-642-1687 from the U.S. or 706-645-9291 from outside the U.S., and using passcode 7381435. The replay will be available through January 28, 2007 at 11:59 p.m. ET. In addition, the webcast will remain available on DOR's website for at least 30 days.

About DOR BioPharma, Inc.

DOR BioPharma, Inc. is a biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec® (oral beclomethasone dipropionate), is a potent, locally-acting corticosteroid being developed for the treatment of GI GVHD, a common and potentially life-threatening complication of bone marrow transplantation. DOR has filed an NDA with the FDA for the treatment of GI GVHD, and has received an FDA PDUFA date of July 21, 2007. An MAA with the EMEA for orBec® has also been filed and validated. orBec® may also have application in treating other gastrointestinal disorders characterized by severe inflammation.

Through its Biodefense Division, DOR is developing biomedical countermeasures pursuant to the recently enacted Project BioShield Act of 2004. DOR's biodefense products in development are recombinant subunit vaccines designed to protect against the lethal effects of exposure to ricin toxin and botulinum toxin. The ricin toxin vaccine, RiVaxTM, has been evaluated successfully in a Phase 1 clinical trial in normal volunteers.

For further information regarding DOR BioPharma, please visit the Company's website located at www.dorbiopharma.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, that reflect DOR BioPharma, Inc.'s current expectations about its future results, performance, prospects and opportunities, including statements regarding the potential use of orBec® for the treatment of gastrointestinal GVHD and the prospects for regulatory filings for orBec®. Where possible, DOR has tried to identify these forward-looking statements by using words such as "anticipates", "believes", "intends", or similar expressions. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. DOR cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including orBec®, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its technologies will prove to be safe and effective, that its cash expenditures will not exceed projected levels, that it will be able to obtain future financing or funds when needed, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the U.S. Government or other countries, that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec® for gastrointestinal GVHD include the risks that: because orBec® did not achieve statistical significance in its primary endpoint in the pivotal Phase III clinical study (i.e. a p-value of less than or equal to 0.05), the FDA may not consider orBec® approvable based upon existing studies, orBec® may not show therapeutic effect or an acceptable safety profile in future clinical trials, if required, or could take a significantly longer time to gain regulatory approval than DOR expects or may never gain approval; DOR is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; or orBec® may not gain market acceptance; and others may develop technologies or products superior to orBec®. These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, DOR's most recent reports on Form 10-QSB and Form 10-KSB. DOR assumes no obligation to update or revise any forward-looking statements as a result of new information, future events, and changes in circumstances or for any other reason.

Source: Business Wire

More News in this Category